CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
Navarixin +1 moredrug
Likely dose
Navarixin 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00688467
NCT00688467Phase 2Completed
CompareCT.gov

A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of SCH 527123 in Subjects With Allergen-Induced Asthma

Merck Sharp & Dohme LLC·interventional·Posted Jun 3, 2008·Updated Jan 2, 2019

In Brief

A Phase 2 clinical trial evaluating Navarixin and Placebo for Asthma. Completed, enrolled 19 participants.

Detailed Summary

Evaluation of treatment in participants with mild asthma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 3, 2008
Enrollment StartJun 1, 2008
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 18.1 years ago

Interventions

Navarixindrug

30 mg capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2

Placebodrug

Matching capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2